Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LANTana: ASTX727 + Lutathera in metastatic NETs
NCT05178693Phase 1Recruiting
- Sponsor
- Imperial College London
- Start
- Apr 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inqovi in neuroendocrine tumors (NETs), sponsored by Imperial College London. Primary endpoint: Re-expression of Somatostatin Receptor-2 at 1 year. Started Apr 2022; status: recruiting.
02
Drugs
inqovi
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT05178693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178693.